


Product Information	
Catalog No.	BS10024
Product name	Anti-Human IL17A & TNFSF13B Bispecific Reference Antibody (Tibulizumab, RUO)
Applications	ELISA, Bioactivity: FACS, Functional assay, Research in vivo
Species reactivity	Human
Host species	Humanized
Clonality	Monoclonal
Isotype	IgG4-kappa-[scFv] ₂
Form	Liquid
Storage buffer	0.01M PBS, pH 7.4.
Concentration	0.71 mg/ml
Purity	>95% as determined by SDS-PAGE.
Purification	Protein A/G purified from cell culture supernatant.
Target	CTLA-8, Cytotoxic T-lymphocyte-associated antigen 8, IL17, IL-17A, IL17A, CTLA8, IL-17, Interleukin-17A, BAFF, ZTNF4, BLYS, Tumor necrosis factor ligand superfamily member 13B, Dendritic cell-derived TNF-like molecule, TALL-1, TNF- and APOL-related leukocyte expressed ligand 1, BLYS, B lymphocyte stimulator, TNFSF13B, CD257, TNFSF20, TALL1, B-cell-activating factor
Expression system	Mammalian Cells
Accession	Q16552 & Q9Y275
Endotoxin level	Please contact with the lab for this information.
Stability and Storage	Use a manual defrost freezer and avoid repeated freeze-thaw cycles. Store at 4°C short term (1-2 weeks). Store at -20°C 12 months. Store at -80°C long term.
Alternative Names	Bispecific, LY 3090106, LY-3090106, LY3090106, 1849636-24-3
Species	Human
Note	For research use only. Not suitable for clinical or therapeutic use.

Background


Tibulizumab (LY-3090106) is a tetravalent bispecific antibody targeting BAFF and IL-17A for the treatment of autoimmune disease.

Image Data



SDS-PAGE for Research Grade Tibulizumab.

SDS-PAGE



Detects Human IL17A in direct ELISAs.